| Endometrial Clear Cell Adenocarcinoma studied in …STUDIED_INderived10 of 39show all (up to 200) |
|---|
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04719273Phase 2 · completed Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer · condition mapped CURATED_BROADER · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05049538recruiting Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01737619NA · active not recruiting PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 39 trials mapped (10 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |